Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by fungi. The
SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the stock notice from SoftOx Solutions AS (the "Company") on 14 August 2025 regarding the financing facility with Long State Investments Limited.
SoftOx Solutions AS: Private Placement resolved
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Reference is made to Soft Softox Solutions AS' (the "Company") notice on 14 August 2025 regarding entering into a financing facility with the global investment fund Long State...
SoftOx Solutions AS: Softox Solutions AS exercises on the financing facility with Long State Investments Limited
Reference is made to the press release dated August 14 2025, regarding the financing facility with Long State Investments Limited ("Long State"). Softox Solutions AS ("SoftOx") today announces that the board of directors has resolved to request the issuance of up to 60 million shares under the financing facility, which will be invested into the Company through a private placement by Long State. This initiate a 10-day pricing period stipulated under the financing agreement.
SoftOx Solutions AS: Refines Clinical Focus and Advances Into Chronic Lung Disease Treatments
Oslo/Copenhagen, September 2nd, 2025 - SoftOx Solutions AS ("SoftOx" or "the Company" - TICKER: SOFTX) today announces a shift in its initial clinical focus towards chronic lung diseases in the upcoming proof-of-concept (POC) trial. It will evaluate the safety of SoftOx Inhalation Solution (SIS) across escalating doses and its effects on pulmonary bacterial load, thereby establishing a foundation for additional clinical advancements.
SoftOx Solutions AS: Private Placement resolved
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Reference is made to Soft Softox Solutions AS' (the "Company") notice on 14 August 2025 regarding entering into a financing facility with the global investment fund Long State...
SoftOx Solutions AS: Softox Solutions secures committed financing facility
Softox Solutions AS ("SoftOx") is pleased to announce that it today has entered into a financing facility with the global investment fund Long State Investments Limited ("Long State") for a total commitment of NOK 50 million over a 24-month period, with the option to extend the facility to NOK 80 million over 36 months.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with fungi.
Contact fungi., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack